
July 11 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:
MILESTONE PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE COMPANY’S RESPONSE TO THE CRL FOR CARDAMYST™ (ETRIPAMIL) NASAL SPRAY
MILESTONE PHARMACEUTICALS INC - FDA ASSIGNS PDUFA ACTION DATE OF DECEMBER 13, 2025
MILESTONE PHARMACEUTICALS INC - EXTENDS $75 MILLION ROYALTY AGREEMENT WITH RTW UNTIL 2025
MILESTONE PHARMACEUTICALS INC - TRANSFERRED DUTIES OF MANUFACTURING TESTING FACILITY TO VENDORS WITH FDA INSPECTION HISTORY